Boston Scientific WATCHMAN FLX™ Left Atrial Appendage Closure Device Demonstrates Superior Bleeding Risk Reduction to Oral Anticoagulation Following a Cardiac Ablation in the OPTION Clinical Trial
Portfolio Pulse from
Boston Scientific's WATCHMAN FLX™ device shows superior bleeding risk reduction compared to oral anticoagulants in the OPTION trial, while maintaining similar stroke risk reduction for atrial fibrillation patients post-cardiac ablation.
November 16, 2024 | 8:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Boston Scientific's WATCHMAN FLX™ device demonstrated superior bleeding risk reduction compared to oral anticoagulants in the OPTION trial, while maintaining similar stroke risk reduction for atrial fibrillation patients post-cardiac ablation.
The positive results from the OPTION trial highlight the effectiveness of Boston Scientific's WATCHMAN FLX™ device, which could lead to increased adoption and sales. This is likely to positively impact BSX's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100